| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-72-6-857 |
| P698 | PubMed publication ID | 5448745 |
| P2093 | author name string | Koch-Weser J | |
| Sidel VW | |||
| Eaton AE | |||
| Kanarek P | |||
| Federman EB | |||
| Finer DC | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sodium | Q658 |
| P304 | page(s) | 857-868 | |
| P577 | publication date | 1970-06-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy | |
| P478 | volume | 72 |
| Q34565772 | 'Old' antibiotics for emerging multidrug-resistant bacteria |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q64084044 | A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia |
| Q91893958 | A DedA Family Membrane Protein Is Required for Burkholderia thailandensis Colistin Resistance |
| Q64059428 | A Review of the Clinical Pharmacokinetics of Polymyxin B |
| Q90283255 | A Study of Multidrug-Resistant, Colistin-Only-Sensitive Infections in Intubated and Mechanically Ventilated Patients Over 2 Years |
| Q43756818 | A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. |
| Q72878734 | Acute Respiratory Failure Secondary to Polymyxin-B Inhalation |
| Q35596685 | Advances in the pharmacotherapy of cystic fibrosis |
| Q40287888 | Adverse antibiotic drug interactions |
| Q38255373 | Adverse reactions associated with systemic polymyxin therapy. |
| Q40417563 | Adverse reactions to anti-infective agents |
| Q92178245 | An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection |
| Q34156349 | Antibiotics and bacterial resistance in the 21st century |
| Q39898335 | Antibiotics and the kidney |
| Q37165591 | Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria |
| Q42908865 | Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia |
| Q38042296 | Antimicrobial peptides and skin: a paradigm of translational medicine |
| Q35662008 | Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics |
| Q37392794 | Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. |
| Q36172505 | Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design |
| Q38186636 | Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q27014993 | Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy |
| Q51795136 | Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. |
| Q36842783 | Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia |
| Q41871984 | Colistin and polymyxin B: a re-emergence |
| Q28082041 | Colistin for lung infection: an update |
| Q34680516 | Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. |
| Q40069157 | Colistin nephrotoxicity in the ICU: Is it different in the geriatric patients? |
| Q35885209 | Colistin neurotoxicity: revisited |
| Q34922728 | Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration |
| Q38840129 | Colistin-Induced Apoptosis of Neuroblastoma-2a Cells Involves the Generation of Reactive Oxygen Species, Mitochondrial Dysfunction, and Autophagy. |
| Q89456253 | Colistin-resistant Escherichia coli carrying mcr-1 in food, water, hand rinse, and healthy human gut in Bangladesh |
| Q38514980 | Colistin: efficacy and safety in different populations. |
| Q40672610 | Colistin: the phoenix arises |
| Q34560321 | Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections |
| Q33938143 | Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis |
| Q36798184 | Comment: Fundamentals and Innovation in Antibiotic Trials |
| Q34124176 | Convulsions in a critically ill patient on hemodialysis: Possible role of low dose colistin |
| Q90358124 | Differences in Colistin-resistant Acinetobacter baumannii Clinical Isolates Between Patients With and Without Prior Colistin Treatment |
| Q39946671 | Drug Selection and Dosage in Renal Insufficiency |
| Q70428959 | Drug Surveillance: Problems and Challenges |
| Q66979566 | Drug toxicity studies and the clinical pharmacologist |
| Q43124623 | Effectiveness and safety of colistin: prospective comparative cohort study |
| Q37187728 | Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii |
| Q90729918 | Efficacy and Safety of Intravenous Colistin in Very Low Birth Weight Preterm Infants |
| Q28539496 | Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis |
| Q38394222 | Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial |
| Q49706174 | Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study |
| Q41728501 | Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies |
| Q38029012 | Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance |
| Q90400600 | Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks |
| Q37204246 | Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium |
| Q92302843 | History, Chemistry and Antibacterial Spectrum |
| Q58790968 | Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment |
| Q47112723 | Illustrative examples of probable transfer of resistance determinants from food animals to humans: Streptothricins, glycopeptides, and colistin |
| Q42945188 | In Vitro Synergistic Antimicrobial Effect of Imipenem and Colistin Against an Isolate of Multidrug-resistant Enterobacter cloacae |
| Q40855475 | In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates. |
| Q35941403 | Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients |
| Q34054315 | Infections in cancer patients |
| Q27486430 | Infectious diseases: annual review of significant publications |
| Q46153446 | Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection |
| Q36574876 | Intravenous Colistin in the treatment of multidrug-resistant Acinetobacter in neonates |
| Q24651466 | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
| Q35563227 | Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis |
| Q34357350 | Intravenous colistin-induced acute respiratory failure: A case report and a review of literature |
| Q42457574 | Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. |
| Q35191353 | Melatonin attenuates colistin-induced nephrotoxicity in rats. |
| Q53720575 | Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic Escherichia coli. |
| Q50046011 | Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy |
| Q36818945 | Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol |
| Q37474441 | Multidrug-resistant Acinetobacter baumannii ventriculitis: successful treatment with intraventricular colistin |
| Q35002302 | Multidrug-resistant Gram-negative infections: what are the treatment options? |
| Q26822729 | Multidrug-resistant bacteria in solid organ transplant recipients |
| Q28363617 | Myopathy caused by polymyxin E: functional disorder of the cell membrane |
| Q90410421 | N-acetylcysteine suppresses colistimethate sodium-induced nephrotoxicity via activation of SOD2, eNOS, and MMP3 protein expressions |
| Q36667079 | Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients |
| Q38746169 | Neurologic Complications of Commonly Used Drugs in the Hospital Setting |
| Q35219637 | Neurotoxic effects associated with antibiotic use: management considerations |
| Q51833021 | Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports. |
| Q37643631 | New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease |
| Q72505337 | New respiratory therapies in cystic fibrosis |
| Q40962296 | Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure |
| Q36268383 | Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options |
| Q36363261 | Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria |
| Q37910022 | Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart review |
| Q40821276 | Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. |
| Q33653353 | Parenteral colistin for the treatment of severe infections: a single center experience |
| Q53682528 | Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. |
| Q37815508 | Pharmacokinetic evaluation of colistin sodium |
| Q39753735 | Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers |
| Q36171581 | Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate |
| Q38994000 | Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? |
| Q64243763 | Plasmid-Mediated Colistin Resistance in : A Review |
| Q53694418 | Plasmid-mediated colistin resistance in animals: current status and future directions. |
| Q54252881 | Polymyxin B causes DNA damage in HK-2 cells and mice. |
| Q35165736 | Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria |
| Q38613051 | Polymyxin B versus colistin: an update |
| Q40128513 | Polymyxin B, Colistin, and Sodium Colistimethate |
| Q83275956 | Polymyxin E-1 (colistin sulphate) (neuro-)intoxication in young ostriches ( Struthio camelus spp.). |
| Q90077041 | Polymyxin Resistance in Klebsiella pneumoniae: Complexity at Every Level |
| Q36786226 | Polymyxin antibiotics for gram-negative infections |
| Q37562099 | Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. |
| Q34675017 | Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice |
| Q37215935 | Polymyxins revisited |
| Q34552966 | Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes |
| Q82669474 | Polymyxins: old antibiotics are back |
| Q36785854 | Population pharmacokinetic analysis of colistin in burn patients. |
| Q47195590 | Population pharmacokinetics of polymyxin B in acutely ill adult patients. |
| Q39903765 | Pseudomonas aeruginosa infections |
| Q35347169 | Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide |
| Q27499294 | Renal and neurological side effects of colistin in critically ill patients |
| Q36700902 | Respiratory Muscle Paralysis Associated With Colistin, Polymyxin B, and Muscle Relaxants Drugs: A Case Report |
| Q40986687 | Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis |
| Q46571062 | Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study |
| Q42546631 | Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock |
| Q33926652 | Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis |
| Q84974907 | Safety in treatment of ventilator‐associated pneumonia due to extensive drug‐resistant Acinetobacter Baumannii with aerosolized colistin in neonates: A preliminary report |
| Q81260156 | Screening for carbapenem-resistant bacteria |
| Q54780754 | Septicaemia in the neutropenic patient. |
| Q47781226 | Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B. |
| Q39066262 | Sex As a Factor in Metabolism, Toxicity, and Efficacy of Pharmacodynamic and Chemotherapeutic Agents |
| Q90643404 | Spread of MCR-3 Colistin Resistance in China: An Epidemiological, Genomic and Mechanistic Study |
| Q34965193 | Sulfamethoxazole-Trimethoprim-Polymyxin Therapy of Serious Multiply Drug-Resistant Serratia Infections |
| Q37150305 | Susceptibility of recent isolates of Pseudomonas aeruginosa to gentamicin, polymyxin, and five penicillins, with observations on the pyocin and immunotypes of the strains |
| Q52577131 | The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa. |
| Q93335300 | The Search for a Practical Method for Colistin Susceptibility Testing: Have We Found It by Going Back to the Future? |
| Q92460320 | The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-β-lactamase |
| Q39240397 | The occurrence of acute renal failure in patients with neuropathic bladders |
| Q74011059 | The pharmacokinetics of colistin in patients with cystic fibrosis |
| Q37954604 | The potential of antimicrobial peptides as biocides |
| Q37041117 | The risk factors of colistin methanesulfonate associated nephrotoxicity |
| Q38586123 | The safety of polymyxin antibiotics |
| Q36280746 | The secondary resistome of multidrug-resistant Klebsiella pneumoniae |
| Q34652418 | The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature |
| Q35592264 | The use of intravenous colistin among children in the United States: results from a multicenter, case series |
| Q24798835 | Toxicity after prolonged (more than four weeks) administration of intravenous colistin |
| Q54285862 | Toxicity of Colistin in Cystic Fibrosis Patients |
| Q21092897 | Toxicity of polymyxins: a systematic review of the evidence from old and recent studies |
| Q44417867 | Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. |
| Q36607401 | Treatment options for multidrug-resistant bacteria. |
| Q40897433 | Unravelling of a mechanism of resistance to colistin in Klebsiella pneumoniae using atomic force microscopy. |
| Q38992007 | Use of Colistin in a Neonatal Intensive Care Unit: A Cohort Study of 65 Patients |
| Q24682618 | Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration |
| Q51010233 | Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea. |
| Q38926250 | Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation |
| Q90295094 | [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation] |
| Q89494968 | mcr-Colistin Resistance Genes Mobilized by IncX4, IncHI2, and IncI2 Plasmids in Escherichia coli of Pigs and White Stork in Spain |
Search more.